CDKN1B Antikörper

Produktnummer ABIN967391

Produktdetails anti-CDKN1B Antikörper

Target: CDKN1B (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B))

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CDKN1B Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunoprecipitation (IP), BioImaging (BI)

Marke: BD Pharmingen™

Kreuzreaktivität: Human

Produktmerkmale: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. This antibody has been developed and certified for the bioimaging application. However, a routine bioimaging test is not performed on every lot. Researchers are encouraged to titrate the reagent for optimal performance.
5. Triton is a trademark of the Dow Chemical Company.

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Mouse p27 [Kip1] (full-length) Recombinant Protein

Klon: G173-524

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Bioimaging
1. Seed the cells in appropriate culture medium at ~10,000 cells per well in an 96-well Imaging Plate and culture overnight.
2. Remove the culture medium from the wells, and fix the cells by adding 100 myl of Fixation Buffer to each well. Incubate for 10 minutes at room temperature (RT).
3. Remove the fixative from the wells, and permeabilize the cells using either 90% methanol, or Triton™ X-100: a. Add 100 myl of -20°C 90% methanol to each well and incubate for 5 minutes at RT. OR b. Add 100 myl of 0.1% Triton™ X-100 to each well and incubate for 5 minutes at RT.
4. Remove the permeabilization buffer, and wash the wells twice with 100 myl of 1× PBS.
5. Remove the PBS, and block the cells by adding 100 myl of to each well. Incubate for 30 minutes at RT.
6. Remove the blocking buffer and add 50 myl of the optimally titrated primary antibody (diluted in Stain Buffer) to each well, and incubate for 1 hour at RT.
7. Remove the primary antibody, and wash the wells three times with 100 myl of 1× PBS.
8. Remove the PBS, and add the second step reagent at its optimally titrated concentration in 50 myl to each well, and incubate in the dark for 1 hour at RT.
9. Remove the second step reagent, and wash the wells three times with 100 myl of 1× PBS.
10. Remove the PBS, and counter-stain the nuclei by adding 200 myl per well of 2 myg/ml Hoechst 33342 in 1× PBS to each well at least 15 minutes before imaging.
11. View and analyze the cells on an appropriate imaging instrument.

Kommentare:

Related Products: ABIN967389

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4°C.

Referenzen für anti-CDKN1B Antikörper (ABIN967391)

Gorospe, Liu, Xu, Chrest, Holbrook: "Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2." in: Molecular and cellular biology, Vol. 16, Issue 3, pp. 762-70, (1996) (PubMed).

Nourse, Firpo, Flanagan, Coats, Polyak, Lee, Massague, Crabtree, Roberts: "Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin." in: Nature, Vol. 372, Issue 6506, pp. 570-3, (1995) (PubMed).

Polyak, Kato, Solomon, Sherr, Massague, Roberts, Koff: "p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest." in: Genes & development, Vol. 8, Issue 1, pp. 9-22, (1994) (PubMed).

Toyoshima, Hunter: "p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21." in: Cell, Vol. 78, Issue 1, pp. 67-74, (1994) (PubMed).

Sherr: "Mammalian G1 cyclins." in: Cell, Vol. 73, Issue 6, pp. 1059-65, (1993) (PubMed).

Details zu CDKN1B

Target: CDKN1B (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B))

Andere Bezeichnung: p27 Kip1 (CDKN1B Produkte)

Synonyme: CDKN4 antikoerper, KIP1 antikoerper, MEN1B antikoerper, MEN4 antikoerper, P27KIP1 antikoerper, cdkn1b antikoerper, sb:cb611 antikoerper, wu:fb63g10 antikoerper, wu:fb64g10 antikoerper, wu:fe18e03 antikoerper, CDKN1B antikoerper, Kip1 antikoerper, p27 antikoerper, FAM14D antikoerper, ISG12 antikoerper, ISG12A antikoerper, P27 antikoerper, Cdki1b antikoerper, AA408329 antikoerper, AI843786 antikoerper, p27Kip1 antikoerper, cdkn1bl antikoerper, cyclin dependent kinase inhibitor 1B antikoerper, cyclin-dependent kinase inhibitor 1Bb antikoerper, interferon alpha inducible protein 27 antikoerper, cyclin-dependent kinase inhibitor 1B antikoerper, cyclin-dependent kinase inhibitor 1Ba antikoerper, CDKN1B antikoerper, cdkn1bb antikoerper, IFI27 antikoerper, Cdkn1b antikoerper, cdkn1ba antikoerper

Hintergrund: Cyclins and cyclin-dependent kinases (cdks) are evolutionarily conserved proteins that are essential for cell-cycle control in eukaryotes. Cyclins (regulatory subunits) bind to cdks (catalytic subunits) to form complexes that regulate the progression of the cell cycle. These complexes are regulated by activating and inhibitory phosphorylation events, as well as by interactions with small proteins that bind to cyclins, cdks, or cyclin-cdk complexes. These include p15, p16, p18, p19, p21 and p27 [Kip1]. p27 [Kip1] has been shown to inhibit the activity of multiple cyclin-cdk complexes, including cyclin D-cdk4, cyclin E-cdk2 and cyclin A-cdk2. p27 [Kip1] is a 27 kD protein which shares N-terminal sequence homology with p21, and like p21, p27 [Kip1] contains a nuclear localization signal in its C-terminal region. IL-2 activation of T cells has been reported to lead to a decrease in p27 [Kip1] and entry into S phase. Removal of IL-2 from T cell cultures results in increased levels of p27 [Kip1] and cell quiescence.

Molekulargewicht: 27 kDa

Pathways: Zellzyklus, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, Sensory Perception of Sound, Mitotic G1-G1/S Phases, DNA Replication, Positive Regulation of Endopeptidase Activity, Synthesis of DNA, Autophagie